339 related articles for article (PubMed ID: 25331391)
21. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
[TBL] [Abstract][Full Text] [Related]
22. Determination of the best prognostic value of serum tumor markers in patients with suspected lung cancer in an Iranian population.
Sigari N; Mohsenpour B; Nikkhoo B; Ghaderi B; Afkhamzadeh A; Azadi NA; Fathi F; Abdi M
Clin Lab; 2014; 60(1):23-7. PubMed ID: 24600971
[TBL] [Abstract][Full Text] [Related]
23. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of serum high-mobility group box 1 detection in esophageal squamous cell carcinoma].
Chen CG; Cui L; Tang P; Yu ZT
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):838-41. PubMed ID: 24061989
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
26. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
27. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
28. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
29. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
[TBL] [Abstract][Full Text] [Related]
30. Elevated tumor markers in patients with pulmonary alveolar proteinosis.
Fang SC; Lu KH; Wang CY; Zhang HT; Zhang YM
Clin Chem Lab Med; 2013 Jul; 51(7):1493-8. PubMed ID: 23314555
[TBL] [Abstract][Full Text] [Related]
31. Novel and convenient method to evaluate the character of solitary pulmonary nodule-comparison of three mathematical prediction models and further stratification of risk factors.
Xiao F; Liu D; Guo Y; Shi B; Song Z; Tian Y; Liang C
PLoS One; 2013; 8(10):e78271. PubMed ID: 24205175
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer.
Wang H; Zhang X; Liu X; Liu K; Li Y; Xu H
J Cancer Res Ther; 2016; 12(1):355-8. PubMed ID: 27072263
[TBL] [Abstract][Full Text] [Related]
33. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
34. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
37. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
38. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer.
Li J; Chen P; Mao CM; Tang XP; Zhu LR
Asia Pac J Clin Oncol; 2014 Jun; 10(2):141-8. PubMed ID: 23551358
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer.
Liu L; Liu B; Zhu LL; Zhang W; Li Y
Bioanalysis; 2012 Oct; 4(19):2367-74. PubMed ID: 23088463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
